Landscape and progress of global peptide drugs in obstetrics and gynaecology

• Published in: Journal of peptide science Vol. 28; no. 12; pp. e3443 - n/a
• Main Authors: Tang, Mi, Cai, Jiang‐hui, Luo, Er‐dan, Diao, Hao‐yang, Huang, Yan, Xiong, Li‐ling, Xing, Sha Sha, Yang, Xiao
• Format: Journal Article
• Language: English
• Published: Bognor Regis Wiley Subscription Services, Inc 01.12.2022
• Subjects: administration route; Clinical trials; ClinicalTrials.gov; drug target; Drugs; Global marketing; Growth rate; Obstetrics; Oral administration; peptide vaccine; Peptides; peptide–drug conjugate; Statistical analysis; Therapeutic targets; Trend analysis; Vaccines
• ISSN: 1075-2617; 1099-1387
• DOI: 10.1002/psc.3443

Peptides have gained popularity in the global market during recent years and have been placed between small molecule drugs and biologics. However, little is known about the comprehensive landscape of peptide drugs in obstetrics and gynaecology. Herein, we analysed new peptide drug‐related clinical trials in obstetrics and gynaecology registered on ClinicalTrials.gov. The number and percentage were used for statistical analysis, and a time trend analysis was conducted by calculating the annual growth rate. We aimed to provide the first overview of the changing landscape and status of global peptide drugs in this prospective field, including exploring drug targets, the cutting‐edge oncotherapy of peptide vaccines and peptide–drug conjugates, and unsolved challenges with oral administration. New peptide drug‐related clinical trials in obstetrics and gynaecology registered on ClinicalTrials.gov were analysed in order to provide the first overview of the changing landscape and status of global peptide drugs in this prospective field. The review highlights drug targets, the cutting‐edge oncotherapy of peptide vaccines and peptide–drug conjugates, and unsolved challenges with oral administration.